2157 — Lepu Biopharma Co Income Statement
0.000.00%
- HK$7.25bn
- HK$7.63bn
- CNY367.79m
Annual income statement for Lepu Biopharma Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 15.6 | 225 | 368 |
Cost of Revenue | |||||
Gross Profit | — | — | 13.6 | 197 | 293 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 520 | 1,010 | 720 | 221 | 759 |
Operating Profit | -520 | -1,010 | -704 | 4.8 | -391 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -613 | -1,029 | -699 | -30.3 | -424 |
Provision for Income Taxes | |||||
Net Income After Taxes | -613 | -1,029 | -699 | -30.3 | -424 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -582 | -1,011 | -689 | -22.1 | -411 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -582 | -1,011 | -689 | -22.1 | -411 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.347 | -0.587 | -0.399 | -0.013 | -0.243 |